Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05704738 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Name: A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — clinical trial record (NCT05704738)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ROCKET-ASTRO

StatusCompleted

PhasePhase 3

SponsorAmgen

Started2023-04-20

View on ClinicalTrials.gov ↗

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent participants.

Amendment history 1 change detected by DataLookout

2026-08-29

Results posted: 2026-08-28

Trial Details

NCT Number	NCT05704738
Lead Sponsor	Amgen
Conditions	Atopic Dermatitis
Enrollment	532 participants
Start Date	2023-04-20
Primary Completion	2025-02-27 (estimated)
Study Completion	2025-11-25 (estimated)
Updated on ClinicalTrials.gov	2026-08-28